As of Sep 22
| +0.18 / +1.08%|
The 10 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 16.50, with a high estimate of 33.00 and a low estimate of 8.00. The median estimate represents a -1.67% decrease from the last price of 16.78.
The current consensus among 10 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.